Business ❯ Healthcare

Pharmaceutical Industry

Drug Development Drug Pricing Drug Manufacturers Market Trends Market Competition Drug Manufacturing Market Analysis Manufacturing Pricing Strategies Company Operations

Eli Lilly Faces High Bar as Q1 Results Arrive Thursday

A 36.8% growth forecast will test momentum from GLP-1 drugs.

Lilly’s Foundayo Start Trails Wegovy as Street Stays Positive

Ligand to Buy XOMA Royalty for $739 Million

Sun Pharma Said to Make $13 Billion All-Cash Offer for Organon

CVS Advances Settlement in FTC Insulin Case Seen as Lifting Market Overhang

Structure’s Oral Obesity Pill Delivers 16.3% Placebo-Adjusted Weight Loss in Phase 2

Trump Touts MFN Drug Deals, Urges GOP to Codify Policy at Doral Retreat

Xenon to Present Topline X-TOLE2 Phase 3 Results in Focal Onset Seizures at 8 A.M. ET Today

Servier to Acquire Day One Biopharma in $2.5 Billion All-Cash Deal at $21.50 a Share

Cantor Raises Innoviva Target to $32 After Q4 Beat on China XacDuro Builds

Lilly Launches FDA-Cleared Monthly Zepbound KwikPen on LillyDirect at $299 Starter Price

Novartis to Exit Listed India Unit in Rs 1,446-Crore Sale to WaveRise–ChrysCapital Consortium

AstraZeneca Posts Strong 2025 Results, Sees Further Growth in 2026

TrumpRx Debuts With 43 Discounted Brand Drugs as Analyses Flag Cheaper Generics and Limits

Trump Launches TrumpRx.gov With Discounts on More Than 40 Medicines, Including GLP-1 Drugs

Eli Lilly’s Q4 Beat and Bullish Outlook Give Way to Stock Drop on Low-Cost GLP-1 Pills

AbbVie Beats Q4 and Raises 2026 Outlook as Shares Fall on Aesthetics, Oncology Concerns

Anvisa Unveils Draft to Authorize Domestic Medicinal Cannabis Cultivation Ahead of March 31 Deadline

Illumina Launches Billion Cell Atlas to Train AI in Drug Discovery

FDA Issues Complete Response Letter for Corcept’s Relacorilant in Cushing’s-Related Hypertension